The 5XFAD mouse model of Alzheimer's disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden

Journal of Alzheimer's Disease

Volumn 46, Issue 1, 2015, Pages 55-61

  Dinkins, Michael B ^a   Dasgupta, Somsankar ^a   Wang, Guanghu ^a   Zhu, Gu ^a   He, Qian ^a   Kong, Ji Na ^a   Bieberich, Erhard ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Alzheimer's disease; amyloid; antibodies; ceramide; exosomes; mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CERAMIDE; IMMUNOGLOBULIN G; PROTEIN; PROTEIN ALIX; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; CALCIUM BINDING PROTEIN; PDCD6IP PROTEIN, MOUSE; PRESENILIN 1;

5XFAD MOUSE; AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EXOSOME; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; AGING; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-BINDING PROTEINS; CERAMIDES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOSOMES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84929330896     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150088     Document Type: Article

References (37)

1. Selkoe DJ. (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3, pii: a004457.
2. Golde TE, Schneider LS, Koo EH (2011) Anti-Aβ therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69, 203-213.
3. Schneider LS, Insel PS, Weiner MW (2011) Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 68, 58-66.
4. Golde TE (2005) The Abeta hypothesis: Leading us to rationally-designed therapeutic Strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15, 84-87.
5. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
6. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360, 672-674.
7. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
8. Bieberich E (2008) Ceramide signaling in cancer and stem cells. Future Lipidol 3, 273-300.
9. Uchida Y (2014) Ceramide signaling in mammalian epidermis. Biochim Biophys Acta 1841, 453-462.
10. Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J, Duerksen Hughes PJ (2012) Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis 29, 537-547.
11. Geekiyanage H, Chan C (2011) MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease. J Neurosci 31, 14820-14830.
12. Han X, Holtzman D, McKeel DW Jr, Kelley J, Morris JC (2002) Substantialsulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82, 809-818.
13. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 1801, 878-886.
14. Barrier L, Ingrand S, Fauconneau B, Page G (2010) Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer's disease. Neurobiol Aging 31, 1843-1853.
15. Geekiyanage H, Upadhye A, Chan C (2013) Inhibition of serine palmitoyltransferase reduces Abeta and tau hyperphos-phorylation in a murine model: A safe therapeutic strategy for Alzheimer's disease. Neurobiol Aging 34, 2037-2051.
16. Wang G, Silva J, Dasgupta S, Bieberich E (2008) Long-chain ceramide is elevatedin presenilin1(PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 56, 449-456.
17. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278, 19777-19783.
18. Jana A, Pahan K (2010) Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: Implications for Alzheimer's disease. J Neurosci 30, 12676-12689.
19. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY (2004) Amyloid-beta peptide induces oligodendrocyte death by activating theneutral sphingomyelinase ceramide pathway. J Cell Biol 164, 123-131.
20. Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23, 178-189.
21. Wang G, Dinkins M, He Q, Zhu G, Poirier C, Campbell A, Mayer-Proschel M, Bieberich E (2012) Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): Potential mechanism of apop-tosis induction in Alzheimer disease (AD). J Biol Chem 287, 21384-21395.
22. Yang DI, Yeh CH, Chen S, Xu J, Hsu CY (2004) Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 17, 99-107.
23. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E (2014) Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 35, 1792-1800.
24. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, Albert M, Varma V, Harris G, Schneider EB, Rabins PV, Bandeen-Roche K, Lyketsos CG, Carlson MC (2012) Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology 79, 633-641.
25. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B, Simons M (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247.
26. Bellingham SA, Guo BB, Coleman BM, Hill AF (2012) Exo-somes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 3, 124.
27. Yuyama K, Sun H, Mitsutake S, Igarashi Y (2012) Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia. J Biol Chem 287, 10977-10989.
28. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
29. Krishnamurthy K, Dasgupta S, Bieberich E (2007) Development and characterization of a novel anti-ceramide antibody. J Lipid Res 48, 968-975.
30. Ly PT, Cai F, Song W (2011) Detection of neuritic plaques in Alzheimer's disease mouse model. J Vis Exp 53, e2831.
31. Irani SR, Gelfand JM, Al-Diwani A, Vincent A (2014) Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Ann Neurol 76, 168-184.
32. Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in atransgenic mouse model of Aβ amyloidosis. J ExpMed 209, 2149-2156.
33. Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Beten-sky R, Wozniak DF, Hyman BT, Holtzman DM (2014) Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. J Neurosci 34, 7281-7292.
34. Vina J, Lloret A (2010) Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 20, S527-S533.
35. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR (1992) Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42, 115-119.
36. Barrier L, Ingrand S, Fauconneau B, Page G (2010) Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer's disease. Neurobiol Aging 31, 1843-1853.
37. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem 280, 28110-28117.